Literature DB >> 14063416

METHYL-HYDRAZINE IN TREATMENT OF HODGKIN'S DISEASE AND VARIOUS FORMS OF HAEMATOSARCOMA AND LEUKAEMIA.

G MATHE, O SCHWEISGUTH, M SCHNEIDER, J L AMIEL, L BERUMEN, G BRULE, A CATTAN, L SCHWARZENBERG.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS; HODGKIN'S DISEASE; HYDRAZINES; LYMPHOSARCOMA; NEOPLASM RADIOTHERAPY; SARCOMA, RETICULUM CELL; VINBLASTINE

Mesh：

Substances：

Year:  1963        PMID： 14063416     DOI： 10.1016/s0140-6736(63)92854-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

1.  NATULAN IN MANAGEMENT OF LATE HODGKIN'S DISEASE, OTHER LYMPHORETICULAR NEOPLASMS, AND MALIGNANT MELANOMA.

Authors:  I D TODD
Journal:  Br Med J       Date:  1965-03-06

2.  THE CHEMOTHERAPY OF MALIGNANT DISEASE--PRACTICAL AND EXPERIMENTAL CONSIDERATIONS.

Authors:  J MATTHIAS
Journal:  Postgrad Med J       Date:  1965-05       Impact factor: 2.401

3.  Chemotherapy of Hodgkin's Disease with Cyclophosphamide, Vinblastine, and Procarbazine.

Authors:  G H Fairley; M J Patterson; R B Scott
Journal:  Br Med J       Date:  1966-07-09

Review 4.  [Diagnostic and therapeutic procedures in Hodgkin's disease].

Authors:  D Huhn; C Steidle
Journal:  Blut       Date:  1973-08

5.  [Long term treatment of advanced vinblastine-resistant lymphogranulomatosis with ibenzmethyzin (Natulan)].

Authors:  E Schulz; H Cissée; K Hausmann
Journal:  Klin Wochenschr       Date:  1970-11-01

6.  [Experiences with methyl-benzyl-hydrazine (Natulan) in lymphoreticular diseases and hemoblastoses].

Authors:  J C Schubert; H Martin
Journal:  Blut       Date:  1968

7.  Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy.

Authors:  Subash C Gupta; David Hevia; Sridevi Patchva; Byoungduck Park; Wonil Koh; Bharat B Aggarwal
Journal:  Antioxid Redox Signal       Date:  2012-01-16       Impact factor: 8.401

8.  Suppressant effect of procarbazine and its comparison with anti-lymphocyte serum in adjuvant-induced polyarthritis in rats.

Authors:  G J Possanza; P B Stewart
Journal:  Clin Exp Immunol       Date:  1970-02       Impact factor: 4.330

Review 9.  Cancer chemotherapy: past, present, and future--Part I.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1984-08       Impact factor: 1.798

Review 10.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.